Andere Sprachen Autolus Therapeutics plc

Aktien

A2JNZJ

US05280R1005

AUTL

Realtime-Estimate Cboe BZX Andere Börsenplätze 16:43:09 25.04.2024			% 5 Tage	% 1. Jan.
4.05 ^USD	-3.80%		-15.21%	-36.80%

19.04.	Europäische Aktien, die in den USA als American Depositary Receipts gehandelt werden, tendieren im Freitagshandel höher, beenden die Woche aber mit einem Minus	MT
18.04.	Europäische Aktien werden in den USA als American Depositary Receipts gehandelt und tendieren am Donnerstag flach	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO	24.04.
Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024	23.04.
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down	19.04.
European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading	18.04.
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading	11.04.
European Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading	08.04.
European Equities Close Lower Tuesday; Eurozone Manufacturing at 3-Month Low; Mining Stocks Rally, Real Estate Drops	02.04.
European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading	02.04.
Autolus Therapeutics Gets European Agency Approval for Marketing Authorization Application for Leukemia Treatment	02.04.
Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL)	02.04.
Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL)	02.04.
Autolus Therapeutics Announces Acceptance of Marketing Authorization Application by the European Medicines Agency for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL)	02.04.
EARNINGS: EPE Special "cautiously optimistic"; RTW Biotech NAV rises	02.04.
Autolus Therapeutics Appoints Mike Bonney as Chair	01.04.
European Equities Traded in the US as American Depositary Receipts Start Week Modestly Higher	01.04.
Autolus Therapeutics Announces Changes to its Board of Directors	01.04.
Autolus Therapeutics Announces Changes to its Board of Directors	01.04.
European Equities Traded in the US as American Depositary Receipts Rise Slightly in Wednesday Trading	27.03.
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading	25.03.
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	21.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Autolus Therapeutics plc

Aktien

A2JNZJ

US05280R1005

AUTL

Andere Sprachen

Filter